The EXACT Moment I Stopped Fearing Dementia

The Wales natural experiment provided the strongest causal evidence to date that the shingles vaccine reduces dementia risk. The vaccine reduced new dementia diagnoses by 3.5% absolute risk (nearly 20% relative) among those actually vaccinated. Follow-up work showed it also lowers risk of mild cognitive impairment and dramatically cuts death rates in those already diagnosed with dementia. The switch to the recombinant vaccine in the US yielded even larger risk reductions. Given the vaccine's excellent safety profile and existing widespread use, it emerges as a rare, simple, one-time intervention with major brain health payoffs.

Hearing loss is now recognized as one of the leading potentially modifiable risk factors for dementia. The systematic review found a clear association between hearing aid use and reduced dementia risk, making this a high-priority, low-risk intervention. The speaker emphasizes it as a simple, powerful step that many people overlook.

The large, two-year RCT found significant gains in global cognition and memory among those taking a daily multivitamin/mineral versus placebo. The two-year brain-aging equivalent is a concrete, communicable metric. Combined with its low cost and safety, this finding makes the multivitamin an attractive foundational supplement for brain health. The speaker also notes that adequate B vitamins are important for omega-3 benefits, reinforcing the value of a comprehensive multivitamin.

The 2019 study highlighted a significant interaction: omega-3 supplementation improved brain performance and reduced dementia symptoms, but only meaningfully when combined with good B-vitamin status. This has led the speaker to advocate for pairing omega-3s with a multivitamin, which also showed cognitive benefits in its own right.

Creatine is widely used for muscle strength, but its role in brain energetics is becoming clearer. The meta-analysis pooled studies testing memory under supplementation and found a significant benefit, especially in older populations. While not yet a standard dementia prevention strategy, its safety profile and low cost make it an attractive option alongside other evidence-based habits.

A large 2020 review identified homocysteine as a key modifiable risk factor for Alzheimer's and advocated for homocysteine-lowering interventions. TMG is a well-tolerated supplement that the speaker includes in his personal regimen. While a dedicated TMG-dementia prevention trial has not been conducted, the pathway is biologically sound, and the speaker sees it as a promising addition.

The speaker has personally adopted this trio after reviewing studies on multivitamins, creatine, and TMG. He takes them as part of a single product (Microvitamin Plus powder) and emphasizes that his personal practice does not constitute medical advice. The stack reflects a pragmatic attempt to combine interventions that each have some degree of evidence for brain health.

In 2013, Welsh health officials set a bright-line rule: only those born on or after 2 September 1933 were eligible for the free shingles vaccine; those born before were never eligible, as they were 80 and deemed less likely to benefit. Researchers compared people born one week before (ineligible, 0.1% vaccine uptake) to those born one week after (eligible, 47.4% uptake). Over 7 years, the eligible group had a 1.3% lower absolute risk of dementia (8.5% relative risk reduction). Using an instrumental variable analysis to estimate the effect among the actually vaccinated, the reduction reached 3.5% absolute and nearly 20% relative risk. The researchers checked that the two groups did not differ in other health behaviors or outcomes, and no other intervention used the same cutoff. The finding implies that thousands of dementia cases could be prevented by a simple, single intervention.

After 2017, the US saw a rapid shift from the live vaccine to the recombinant one. Researchers exploited this natural switch, similar to the Wales study, and found that those receiving the recombinant vaccine had an even lower risk of dementia. This directly addresses the worry and suggests the real-world benefit of the currently available vaccine might be larger than what the Wales study measured.

Using the same Welsh birthdate cutoff, researchers examined outcomes beyond new dementia diagnoses. The vaccine appeared to reduce new diagnoses of mild cognitive impairment (an earlier transitional stage). Even more striking, among individuals who had already received a dementia diagnosis before the vaccine program began, vaccination reduced the death rate over 9 years from nearly 50% by about 30 percentage points. While confidence intervals were wide, the magnitude is remarkable. This suggests the vaccine can both prevent and slow cognitive decline.

Mouse experiments show that viruses stimulate the production of the same protein that forms amyloid plaques, creating a defense that backfires by accelerating Alzheimer's pathology. The varicella-zoster virus, which causes chickenpox, remains latent in the body and can reactivate subclinically, causing chronic neuroinflammation. It also damages cerebral blood vessels, contributing to vascular dementia. By suppressing these reactivations, the shingles vaccine may interrupt a key driver of both major dementia types.

The trial randomized participants to receive a daily multivitamin/mineral or placebo for two years. Those on the supplement showed relative improvements in overall cognition and memory scores. The effect size translated to a two-year slower pace of brain aging, a clinically meaningful difference. This finding positions a standard multivitamin as a pragmatic, low-risk intervention to support cognitive health in aging.

The meta-analysis pooled studies comparing creatine supplementation to placebo on memory tasks. Creatine improved memory overall, and the effect was stronger in older adults, who may have lower brain creatine levels or higher oxidative stress. This suggests creatine could be a simple, affordable supplement to support memory with aging, though long-term dementia prevention trials are lacking.

TMG acts as a methyl donor, converting homocysteine back to methionine. The speaker posits that by lowering homocysteine, TMG could reduce Alzheimer's risk. While not yet proven in a dedicated dementia prevention trial, the biological pathway is plausible, and TMG is already used by the speaker as part of his brain-health supplement stack.

The systematic review compared dementia risk in hearing-impaired individuals who did or did not use hearing aids. Users had substantially lower risk of cognitive decline and dementia. This positions hearing correction as one of the simplest and most impactful steps for brain health in later life.